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alopathy affects about 4 percent of patients with the
acquired immunodeficiency syndrome (AIDS), and
survival after the diagnosis of leukoencephalopathy
averages only about three months. There have been
anecdotal reports of improvement but no controlled
trials of therapy with antiretroviral treatment plus in-




In this multicenter trial, 57 patients with
human immunodeficiency virus (HIV) infection and
biopsy-confirmed progressive multifocal leukoen-
cephalopathy were randomly assigned to receive one
of three treatments: antiretroviral therapy alone, an-
tiretroviral therapy plus intravenous cytarabine, or
antiretroviral therapy plus intrathecal cytarabine. Af-
ter a lead-in period of 1 to 2 weeks, active treatment
was given for 24 weeks. For most patients, antiretro-





At the time of the last analysis, 14 pa-
tients in each treatment group had died, and there
were no significant differences in survival among




0.85 by the log-rank test). The
median survival times (11, 8, and 15 weeks) were
similar to those in previous studies. Only seven pa-
tients completed the 24 weeks of treatment. Anemia
and thrombocytopenia were more frequent in pa-
tients who received antiretroviral therapy in combi-





Cytarabine administered either intra-
venously or intrathecally does not improve the prog-
nosis of HIV-infected patients with progressive mul-
tifocal leukoencephalopathy who are treated with
the antiretroviral agents we used, nor does high-
dose antiretroviral therapy alone appear to improve
survival over that reported in untreated patients.
(N Engl J Med 1998;338:1345-51.)
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 results from infection with a human










 It is estimated to af-






therapy has been established.
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Suspicion of progressive multifocal leukoencepha-
lopathy is aroused by characteristic clinical and neuro-
radiologic abnormalities in an immunocompromised
host. Other disorders, including cytomegalovirus in-
fection, central nervous system lymphoma, and en-
cephalitis caused by infection with the human im-
munodeficiency virus (HIV), may mimic progressive
multifocal leukoencephalopathy, and definitive diag-
nosis requires the evaluation of tissue. Stereotactic





 Recent studies indicate that the presence of
JC virus in cerebrospinal fluid, as identified by the
polymerase chain reaction (PCR), has high specific-





vival after diagnosis in HIV-infected patients ranges









mission, prolonged survival, and even spontaneous




 Berger et al. have
estimated that in approximately 7 percent of pa-
tients, progressive multifocal leukoencephalopathy





Treatment with prednisone, acyclovir, vidarabine
(given either intravenously or intrathecally), HLA-
matched platelets, and interferon alfa have not re-






patients with AIDS, both antiretroviral agents and
cytarabine have been found to be efficacious in some
small, uncontrolled studies but not in others. Such
reports have led to the frequent use of cytarabine in
patients with AIDS who have progressive multifocal
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leukoencephalopathy. Because cytarabine has severe
side effects, including immune suppression, this un-
established therapy entails considerable risk.
AIDS Clinical Trials Group (ACTG) Study 243 was
a multicenter study comparing antiretroviral medi-
cation alone with antiretroviral therapy plus cytara-
bine for the treatment of progressive multifocal leu-
koencephalopathy in HIV-infected subjects. The
protocol ensured that the diagnosis of progressive







This trial was a randomized, multicenter, open-label study, de-
signed to enroll 90 patients of either sex. All subjects had HIV
type 1 infection and clinical and radiologic findings indicative of
progressive multifocal leukoencephalopathy. All subjects were re-
quired to have the diagnosis established within two months of
study entry. Tissue obtained by stereotactic brain biopsy was eval-
uated both by standard neuropathological examination at the





ed at the National Institute of Neurological Disorders and Stroke.
Subjects were eligible only if at least one of these tests confirmed
the diagnosis. Cerebrospinal fluid was evaluated by PCR for the
presence of JC virus in a number of subjects. Other criteria for
inclusion were an age of 18 to 65 years, an absolute neutrophil
count of 750 cells per cubic millimeter or higher, a platelet count
of 50,000 per cubic millimeter or higher, serum concentrations
of alanine aminotransferase, aspartate aminotransferase, or both
that were less than five times the upper limit of normal, the ability
to provide informed consent or the assignment of a durable pow-
er of attorney, and, in the case of women, a negative serum preg-
nancy test and use of adequate contraception throughout the
study.
Exclusion criteria included the administration within the past
14 days of interferon, ganciclovir, foscarnet, antiretroviral therapy
other than zidovudine, didanosine, or zalcitabine, or experimental
drugs for the treatment of progressive multifocal leukoencepha-
lopathy; systemic chemotherapy for cancer; prior treatment with
cytarabine; an active opportunistic infection; conditions preclud-
ing the placement of an Ommaya reservoir; intolerance of all the
antiretroviral medications used in the study; allergy to or intoler-
ance of filgrastim (granulocyte colony-stimulating factor); and
other life-threatening complications likely to cause death within
three months.
An ACTG neurologist conducted all neurologic evaluations.
Optimal antiretroviral therapy was determined during a lead-in
period of one to two weeks; the preferred therapy was 300 mg of
zidovudine three times a day and 200 mg of didanosine (125 mg
if the patient weighed less than 60 kg) twice a day. Subjects al-
ready receiving zalcitabine and those with a history of intolerance
of didanosine received 0.75 mg of zalcitabine three times a day
in addition to zidovudine. Subjects who were unable to tolerate
either didanosine or zalcitabine could enter the study and receive
zidovudine alone. Before enrollment was completed, new antiret-
roviral agents were approved by the Food and Drug Administra-
tion and were permitted in the study.
After the lead-in period, subjects were randomly assigned to
one of three treatments, each of which was given for 24 weeks.
Group 1 continued to receive the antiretroviral regimen estab-
lished during the lead-in period, with dose adjustments to reduce
or eliminate toxic effects. Group 2 continued to receive the estab-
lished antiretroviral regimen and also received 4 mg of cytarabine
per kilogram of body weight daily for 5 days by intravenous infu-
sion, followed by a 16-day period when antiretroviral therapy
alone was given. This 21-day cycle was repeated throughout the
study. Group 3 received antiretroviral therapy plus 50 mg of cy-
tarabine, administered intrathecally with an Ommaya reservoir,
once a week for four weeks, then once every two weeks for eight
weeks, then once every four weeks for the remainder of the study.
Filgrastim was administered to all subjects in group 2 after each
five-day cycle of cytarabine; it was administered to patients in the
other groups when required to counteract neutropenia.
An external performance and safety monitoring board closely
monitored the study. A first interim review was conducted at 18
months; on the basis of the interim results, the board recom-
mended that the study continue. A second interim review was
conducted when 50 percent of the expected events had occurred.
After the second review, the board concluded that no treatment
was likely to show a survival benefit, even if the study were con-
tinued to completion. On the basis of that recommendation, the




An intention-to-treat analysis was performed that included all
eligible subjects randomly assigned to the three treatment groups.
Kruskal–Wallis and Fisher’s exact tests were used to compare con-
tinuous and discrete measures, respectively, among the treatment
groups. Differences in the length of time to the occurrence of a
first adverse effect due to drug toxicity and the length of time to
death were tested by the log-rank test. The Kaplan–Meier meth-
od was used to estimate survival in the three groups.
Analyses were based on stochastic curtailment methods for the
primary end point (survival). These methods were used to esti-
mate the conditional power of the study if it were to be complet-
ed, given the observed data up to each interim analysis. These es-
timates were derived by simulation and by analytic techniques,







The study was open for enrollment from April
1994 to August 1996. Sixty-four patients were en-
rolled at 13 ACTG sites. The study was approved by
the institutional review board at each site, and all
subjects provided written informed consent. Data
on 62 patients enrolled before May 1996 were avail-
able during the second (final) interim analysis. Three
subjects were lost to follow-up or withdrew during
the lead-in period and were therefore not randomly
assigned to a treatment group. Brain biopsies were
positive in 49 patients by both methods (Table 1);
3 subjects were positive on in situ hybridization but
not on microscopical examination; 5 were positive
on microscopical analysis but not on in situ hybrid-
ization. Two additional patients were considered in-
eligible, since neither the neuropathological nor the
in situ evaluation confirmed the diagnosis. The re-
ported results are thus based on 57 patients who
could be evaluated. One of these did not receive any
study medication.
Most of the patients were men (82 percent), and
65 percent were non-Hispanic whites. As Table 2
shows, their median age was 38 years (range, 26 to
54), and they had a median of 13 years of education
(range, 9 to 18). The overall median Karnofsky




count (53; range, 0 to 420) reflects the advanced
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stage of HIV disease in this cohort. Twenty patients
were randomly assigned to the intravenous-cytara-
bine group (group 2), 19 to the intrathecal-cytara-
bine group (group 3), and 18 to the antiretroviral-
therapy-only group (group 1). After randomization,
the intravenous-cytarabine group was found to con-




0.015 for the compari-





comparison between all patients who received cytar-
abine and those who did not). With the exception
of sex, there were no significant differences in base-
line characteristics among the treatment groups.
At base line, the following abnormalities and
symptoms were present: diminished cognitive func-
tion in 79 percent of the patients, motor-coordina-
tion defects in 77 percent, sensory loss in 47 per-
cent, visual loss in 39 percent, headache in 28
percent, and seizures in 16 percent. No significant
differences were detected when we compared the
three treatment groups (or when we compared the
two groups receiving cytarabine with that receiving
only antiretroviral therapy) with respect to neuro-
logic history and signs, symptoms, or abnormalities
in blood chemistry at base line. Subjects receiving
only antiretroviral therapy had, on average, signifi-
cantly lower absolute neutrophil counts than the









three-way and two-way comparisons, respectively),









0.083, respectively). The treatment groups did
not differ significantly with respect to the frequency
of any other hematologic abnormality at base line.
The majority of subjects (44, or 77 percent) had
received zidovudine before entering the study. Di-
danosine alone or in combination had been taken by
21 patients (37 percent), stavudine by 14 patients
(25 percent), and zalcitabine by 8 patients (14 per-
cent). A history of treatment with saquinavir in
combination with other antiretroviral agents was re-
ported by three patients (5 percent; one in the in-
travenous-cytarabine group and two in the intrathe-
cal-cytarabine group), and a history of ritonavir
treatment by one patient in the intrathecal-cytara-
bine group. Seven patients did not report any prior




All 57 patients, including those who successfully
completed 24 weeks of therapy, were followed while
receiving the assigned drug until the end of the
study or until they died. The median follow-up was
8.7 weeks and did not differ significantly among the









the log-rank test for the three-way and two-way
comparisons, respectively).
Seven patients completed the 24-week treatment.
Three (one in each group) who were receiving active
therapy at the time the study was terminated discon-
tinued treatment at that time. Table 3 lists the rea-
sons for permanent discontinuation of treatment.
 
*The diagnosis could be confirmed on brain biopsy by





























































































Both positive 18 (90)








Both positive 16 (84)
Only neuropathological examination positive 2 (11)








Both positive 15 (83)
Only neuropathological examination positive 1 (6)
Only in situ hybridization positive 2 (11)
*P values were calculated with the Kruskal–Wallis nonparametric test.
†The Karnofsky performance score, a measure of functional ability, ranges from 0 to 100, with







































































































Age (yr) 38 (26–54) 37.5 (26–50) 38 (33–54) 39 (28–53) 0.68
Education (yr) 13 (9–18) 14 (11–17) 12 (9–18) 13 (12–18) 0.20









) 53 (0–420) 106 (0–220) 29 (0–420) 53 (0–211) 0.09
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Twenty-two patients (39 percent) died during the
study. One patient in the intrathecal-cytarabine group
and one in the intravenous-cytarabine group discon-
tinued treatment because of thrombocytopenia, as
required by the protocol. Treatment was never dis-
pensed to one patient in the antiretroviral-therapy-
only group. Fourteen patients discontinued treat-
ment at their own request, four at the request of the
investigators, five because of drug-induced toxicity,
and one at the start of other experimental treatment.
The majority of the patients who discontinued treat-
ment at their own or an investigator’s request had
been randomly assigned to receive intrathecal cytar-
abine (11 patients). The median length of treatment
was longer for the antiretroviral-therapy-only group
(8.9 weeks, vs. 6.4 weeks for the two cytarabine
groups combined), but the difference was not signif-
icant (P
 
0.56 and P0.29, respectively, by the log-
rank test).
The median time to the first dose modification in
the group receiving only antiretroviral therapy was
more than double that in the two groups receiving
cytarabine (P0.03 and P0.01 for the three-way
and two-way comparisons, respectively, by the log-
rank test). Thirteen of the 57 patients died while re-
ceiving the full dose of antiretroviral therapy and
cytarabine (23 percent), and only 2, who were re-
ceiving antiretroviral therapy alone, completed treat-
ment without any dose modification (4 percent).
The chief reason for dose modification was a deci-
sion by the clinician or the patient (28 percent); this
was particularly common in the intrathecal-cytara-
bine group (47 percent). The second-most-com-
mon reason overall (19 percent), and the common-
est reason in the intravenous-cytarabine group (37
percent), was hematologic toxicity.
As antiretroviral medication, 29 patients (51 per-
cent) received zidovudine combined with didano-
sine, 7 (12 percent) received zidovudine plus zalcit-
abine, and 7 (12 percent) received zidovudine alone.
In addition to this therapy, 15 patients received sta-
vudine, 5 lamivudine, 5 saquinavir, and 1 ritonavir.
Saquinavir was given in combination with zidovu-
dine and lamivudine to three patients and in com-
bination with stavudine and lamivudine to one
patient. Ritonavir was used in combination with zi-
dovudine in one patient. Five subjects received other
drug combinations containing zidovudine. Two pa-
tients received didanosine alone, and two zalcitabine
alone. Compliance with antiretroviral therapy was
assessed every 4 weeks and was consistently rated as
good (more than 80 percent of medication taken)
for the majority of the patients (90 percent) through-
out the 24-week protocol.
Safety
The standardized ACTG scale for grading toxicity
assigns a value from 0 to 5 to clinical and laboratory
abnormalities, according to their severity. Twenty-
three patients had drug-induced laboratory abnor-
malities rated grade 3 or higher. A larger number of
patients in the intravenous-cytarabine group (11 of
20 patients [55 percent]) than in the other groups
had laboratory evidence of drug toxicity, but the dif-
ferences were not significant (P0.22 and P0.81
for the three-way and two-way comparisons, respec-
tively, by the log-rank test).
No significant difference was detected among the
groups with respect to blood chemical abnormalities
(three patients in the antiretroviral-therapy-only group
had such toxic effects, as did two in the intravenous-
cytarabine group and one in the intrathecal-cytara-
bine group). Nineteen patients had evidence of he-
matologic toxicity rated grade 3 or higher during
*Fifty-seven eligible patients were randomly assigned to treatment, of whom one (in the antiret-
roviral-therapy-only group) never received the study medication. Percentages have been calculated
with the number receiving treatment as the denominator.
†Of the 10 patients who completed treatment, 3 (1 in each study group) did so at the time of
study termination.
TABLE 3. REASONS FOR DISCONTINUATION OF THE STUDY DRUGS,















Death 22 (39) 11 (55) 4 (21) 7 (41)
Patient’s request 14 (25) 3 (15) 8 (42) 3 (18)
Completion of therapy† 10 (18) 3 (15) 3 (16) 4 (24)
Investigator’s request 4 (7) 0 3 (16) 1 (6)
Drug toxicity 5 (9) 3 (15) 1 (5) 1 (6)
Experimental medication 1 (2) 0 0 1 (6)
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the 24-week treatment period; the majority (10 pa-
tients) were in the intravenous-cytarabine group (50
percent of that group had such effects) (Table 4).
Toxic effects (grade 3 or higher) on hemoglobin and
platelet counts were more common and occurred
earlier in the intravenous-cytarabine group than in
the other two groups (P0.05 and P0.01, respec-
tively, for the three-way comparisons and P0.22
and P0.01, respectively, for the two-way compari-
sons, by the log-rank test). No statistically signifi-
cant difference was detected in effects on the abso-
lute neutrophil counts. Hematologic toxicity was the
primary reason for dose modification in the intrave-
nous-cytarabine group, but only one patient perma-
nently discontinued treatment for this reason. Thus,
the time to the first dose modification differed sig-
nificantly among groups, whereas the time to per-
manent discontinuation of treatment did not.
Twenty patients had signs or symptoms of toxicity
rated grade 3 or higher during follow-up (nine, sev-
en, and four in the intravenous-cytarabine, intrathe-
cal-cytarabine, and antiretroviral-therapy-only groups,
respectively). No significant differences were detect-
ed among the treatment groups.
Survival
Forty-two patients had died by the time the last
analysis was performed (14 in each treatment
group). Thirty-seven (88 percent) died of progres-
sive multifocal leukoencephalopathy, two of pro-
gressive HIV disease, one of Pneumocystis carinii
pneumonia, one of sepsis, and one of an unknown
cause. Figure 1 shows the Kaplan–Meier survival
curves for each of the three treatment groups; no
significant difference among the groups was detect-
ed (P0.85 by the log-rank test). The intravenous-
cytarabine group had the lowest median survival (7.6
weeks), but there were also four long-term survivors
in this group who were still alive beyond week 60;
however, two of the long-term survivors discontin-
ued treatment early (during the first and seventh
weeks of the study). No significant difference was
found when we compared the antiretroviral-therapy-
only group with the two cytarabine groups com-
bined (P0.85 by the log-rank test).
At the time of the last analysis in July 1996, the
performance and safety monitoring board had 59
percent of the information that would have been
available if the study had continued to the originally
intended end point (42 of the 71 deaths predicted
by the completion of the trial had occurred). Con-
ditional power, a measure of the chance of detecting
a significant increase in the survival rate under dif-
ferent alternative assumptions, given the observed
data patterns up to the time of the analysis, was cal-
culated both by simulation and analytically (stochas-
tic curtailment methods). The two alternatives con-
sidered in calculating the conditional power of the
study were the continuation of the observed trend
for the rest of the study and a doubling of survival
among the remaining patients due to the effect of
cytarabine. The conditional-power estimates, calcu-
lated analytically, were 0.4 percent when the three
groups were compared and 15 percent when the cy-
tarabine groups were combined (simulated values,
0.2 percent and 20 percent, respectively). Thus, there
was no more than a 20 percent chance of rejecting
the null hypothesis that there was no difference
in survival among the treatments even if all future
data supported the alternative hypothesis that cytar-
abine increases survival. The board concluded at
that point that the study should be discontinued
*Fifty-seven patients were randomly assigned to treatment, of whom one (in the antiretroviral-ther-
apy-only group) never received the study medication. Percentages have been calculated with the num-
ber receiving treatment as the denominator.
†P values were calculated by the log-rank test, for the comparison of time to the occurrence of the
first toxic effect.



















Hemoglobin, 6.5 g/dl 3 (5) 3 (15) 0 0 0.05 0.22
Absolute neutrophil count, 
749/mm3
12 (21) 4 (20) 3 (16) 5 (29) 0.68 0.41
Platelet count, 49,999/mm3 11 (20) 8 (40) 3 (16) 0 0.01 0.01
Any of these effects 19 (34) 10 (50) 4 (21) 5 (29) 0.13 0.52
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and the results disseminated in order to spare pa-
tients from undergoing an intense, invasive, and in-
effective therapy.
DISCUSSION
Most of the literature on the effect of antiretrovi-
ral therapy alone and in combination with intrave-
nous or intrathecal cytarabine for the treatment of
progressive multifocal leukoencephalopathy in pa-
tients with AIDS has been anecdotal and conflict-
ing. Some investigators have reported improvement
in patients with AIDS and suspected or biopsy-
proved progressive multifocal leukoencephalopathy
after the administration of zidovudine or other an-
tiretroviral agents,21-23 but not all investigators have
had similar results.24 There have also been reports of
improvement in non–HIV-related progressive multi-
focal leukoencephalopathy when cytarabine has been
given intravenously, intrathecally, or both,25-27 and
there are similar reports of improvement in patients
with AIDS.21,28-30 Some patients appeared to respond
to intravenous cytarabine, others to intrathecal cy-
tarabine, and some to a combination. On the other
hand, Urtizberea et al. found no benefit of intrave-
nous and intrathecal cytarabine.31 Fong et al., in a
prospective and retrospective study of 28 patients,
found no benefit in the 9 who had been treated with
cytarabine.32 In addition, although cytarabine has an
antiviral effect in cell culture,33 a therapeutic effect
in vivo has not been established.34,35
ACTG Study 243 was a prospective investigation
of progressive multifocal leukoencephalopathy that
was designed to address several important issues. To
ensure that the approximately 7 percent of patients
who appear to have a more benign course were not
overrepresented, subjects were required to have pro-
gressive multifocal leukoencephalopathy diagnosed
within two months of study entry. All diagnoses
were confirmed in brain-biopsy specimens by either
typical neuropathological findings or in situ hybrid-
ization for JC virus. The in situ hybridization was
performed at a central site where the investigators
had the requisite expertise (the laboratory of Dr.
Major at the National Institute of Neurological Dis-
orders and Stroke).
Enrollment of patients and prevention of with-
drawals are difficult in clinical trials of rapidly pro-
gressive diseases with high fatality rates. Further dif-
ficulties associated with the current trial included
the frequency of concomitant disabling HIV-related
illnesses, the need for subjects to undergo brain bi-
opsy, and the side effects of the prescribed medica-
tions, both the antiretroviral drugs and cytarabine.
To make the evaluation of effects of medication
more accurate, subjects likely to die from causes oth-
er than progressive multifocal leukoencephalopathy
in less than three months were not enrolled, and
most subjects did not have progressive multifocal
leukoencephalopathy at a stage that was so advanced
as to preclude a therapeutic effect if cytarabine had
been effective.
We believe our negative results have direct rele-
vance to clinical practice. Although there was no
double-placebo group (i.e., no group that received
neither antiretroviral drugs nor cytarabine), the me-
dian survival (1.75 to 3.5 months) was very close to
that predicted from a review of the literature (2.5 to
4 months), indicating that antiretroviral therapy had
no benefit. There were also no significant differences
between the group treated with antiretroviral drugs
alone and the groups that received intravenous or
intrathecal cytarabine. This study was conducted be-
fore the advent of highly active antiretroviral thera-
py, which has been reported to be associated with
regression of progressive multifocal leukoencepha-
lopathy.36,37 Our results provide useful comparative
data for future studies incorporating highly active
antiretroviral therapy, as well as agents more specifi-
cally directed against JC virus.
Supported by grants (1 PO1 NS3228, A1-25868, RR00036-37,
RR00046, RR00051, RR00722, NS26643, and AI25915) from the Na-
tional Institutes of Health and by the AIDS Clinical Trials Group, National
Institute of Allergy and Infectious Diseases.
APPENDIX
The following persons made a substantial contribution to the conduct,
design, and analysis of the study: Z. Antonijevic, Harvard School of Public
Health, Boston; J. Berger, University of Kentucky School of Medicine, Lex-
ington; J. Booss, Veterans Affairs Medical Center, West Haven, Conn.; M.
Chappell, Community Constituency Group, San Francisco; P. Clax, Divi-
sion of AIDS, Bethesda, Md.; B. Dezube, Beth Israel Deaconess Medical
Center, Boston; M. Donovan Post, University of Miami, Miami; C. Petti-
Figure 1. Kaplan–Meier Curves for Survival in the Three Treat-
ment Groups.
The median survival was 8 weeks in the intravenous-cytarabine
group (in which 14 of 20 patients died), 15 weeks in the intra-
thecal-cytarabine group (14 of 19 patients died), and 11 weeks
in the antiretroviral-therapy-only group (14 of 18 patients died).
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nelli and L. Purdue, National Institute of Allergy and Infectious Diseases,
Bethesda, Md.; S. Shriver, Social and Scientific Systems, Rockville, Md.; R.
Levy, Northwestern University, Evanston, Ill.; K. Robertson, University of
North Carolina, Chapel Hill; C. Marra, University of Washington, Seattle;
B. Navia, Massachusetts General Hospital and Harvard Medical School,
Boston; P. Jatlow, Yale University School of Medicine, New Haven,
Conn. The following pharmaceutical companies provided both expertise
and study medications: Amgen (R. Wong); Bristol-Myers Squibb (C.
McLaren); Burroughs Wellcome (J. Rooney); Hoffmann–LaRoche (M.
Salgo); Upjohn (R. Earhart). The members of the performance and safety
monitoring board were as follows: B. Jubelt (chair), State University of
New York Health Science Center, Syracuse; B. Barton, Maryland Medical
Research Institute, Baltimore; J. Noseworthy, Mayo Clinic, Rochester,
Minn.; L. Sharer, New Jersey Medical School, Newark. The participating
AIDS Clinical Trials Units and investigators were as follows: Albany Med-
ical College, Albany, N.Y. (S. Remick); Columbia–Presbyterian Medical
College, New York (M. Crawford, J. Dobkin, G. Dooneief, and K. Mard-
er); Johns Hopkins University, Baltimore (R. Becker, K. Carter, A. Khan,
and V. Rexrod); Massachusetts General Hospital and Harvard Medical
School, Boston (T. Flynn, M. Hirsch, and E. McCarthy); Mount Sinai
Medical Center, New York (E. Chusid, P. Gerits, H. Mendoza, and H.
Sacks); Northwestern University, Evanston, Ill. (C. Cooper, R. Murphy,
and J. Phair); University of California, San Francisco (S. Forstat, D. Gary,
and D. McGuire); University of Cincinnati, Cincinnati; University of Col-
orado Health Sciences Center, Denver (S. Canmann and K. Tyler); Univer-
sity Hospitals of Cleveland, Cleveland (S. Weaver, S. Gordon); University
of North Carolina, Chapel Hill (E. Atos Radzion and W. Robertson); Uni-
versity of Washington, Seattle (A. Collier, C. Cooper, and J. Lund); Wash-
ington University School of Medicine, St. Louis (M. Glicksman, J.
Voorhees, and M. Royal).
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